FIG. 7.

Recombinant VIG protects mice against VACV challenge in vivo. Groups of eight mice were treated with recombinant VIG (orange circles) or commercial, plasma-derived VIG (gray diamonds) at the indicated doses 24 h before (solid lines) or after (broken lines) challenge with VACV (Lister strain or NYCBOH strain). Tail lesions were enumerated in a blinded fashion 7 days after virus challenge, and the results are expressed relative to the negative control (anti-rhesus D polyclonal antibody [57]). Data are shown as means ± standard errors of the means.